Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Role of lipoprotein-associated phospholipase A2 in atherosclerosis.

Literature DB >> 18489851

Role of lipoprotein-associated phospholipase A2 in atherosclerosis.

Shahar Lavi¹, Joerg Herrmann, Ronit Lavi, Joseph P McConnell, Lilach O Lerman, Amir Lerman.

Abstract

Lipoprotein-associated phospholipase A(2)(Lp-PLA(2)) is a biomarker that can be used to assess the risk for cardiovascular disease and events. In addition to being a useful marker of a risk factor, several studies suggest that Lp-PLA(2) has a pathophysiologic role in the atherosclerotic disease process. In this article, we review this aspect and its therapeutic implications.

Entities: Disease Gene

Mesh：

Substances：

Year: 2008 PMID： 18489851 DOI： 10.1007/s11883-008-0036-9

Source DB: PubMed Journal: Curr Atheroscler Rep ISSN： 1523-3804 Impact factor: 5.113

46 in total

1. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction.

Authors: J A Suwaidi; S Hamasaki; S T Higano; R A Nishimura; D R Holmes; A Lerman
Journal: Circulation Date: 2000-03-07 Impact factor: 29.690

2. Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein.

Authors: Willibald Maier; Lukas A Altwegg; Roberto Corti; Steffen Gay; Martin Hersberger; Friedrich E Maly; Gabor Sütsch; Marco Roffi; Michel Neidhart; Franz R Eberli; Felix C Tanner; Sharon Gobbi; Arnold von Eckardstein; Thomas F Lüscher
Journal: Circulation Date: 2005-03-07 Impact factor: 29.690

3. Platelet-activating factor acetylhydrolase prevents myocardial ischemia-reperfusion injury.

Authors: E N Morgan; E M Boyle; W Yun; J C Kovacich; T G Canty; E Chi; T H Pohlman; E D Verrier
Journal: Circulation Date: 1999-11-09 Impact factor: 29.690

Review 4. Phospholipase A(2) in vascular disease.

Authors: E Hurt-Camejo; G Camejo; H Peilot; K Oörni; P Kovanen
Journal: Circ Res Date: 2001-08-17 Impact factor: 17.367

5. Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study.

Authors: Carlos Iribarren; Myron D Gross; Jeanne A Darbinian; David R Jacobs; Stephen Sidney; Catherine M Loria
Journal: Arterioscler Thromb Vasc Biol Date: 2004-10-21 Impact factor: 8.311

6. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma.

Authors: Irene Gazi; Evangelia S Lourida; Theodosios Filippatos; Vasilis Tsimihodimos; Moses Elisaf; Alexandros D Tselepis
Journal: Clin Chem Date: 2005-10-13 Impact factor: 8.327

7. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.

Authors: Marc S Sabatine; David A Morrow; Michelle O'Donoghue; Kathleen A Jablonksi; Madeline Murguia Rice; Scott Solomon; Yves Rosenberg; Michael J Domanski; Judith Hsia
Journal: Arterioscler Thromb Vasc Biol Date: 2007-08-31 Impact factor: 8.311

8. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.

Authors: James A de Lemos; Michael A Blazing; Stephen D Wiviott; Eldrin F Lewis; Keith A A Fox; Harvey D White; Jean-Lucien Rouleau; Terje R Pedersen; Laura H Gardner; Robin Mukherjee; Karen E Ramsey; Joanne Palmisano; David W Bilheimer; Marc A Pfeffer; Robert M Califf; Eugene Braunwald
Journal: JAMA Date: 2004-08-30 Impact factor: 56.272

9. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study.

Authors: Ramachandran S Vasan; Lisa M Sullivan; Ronenn Roubenoff; Charles A Dinarello; Tamara Harris; Emelia J Benjamin; Douglas B Sawyer; Daniel Levy; Peter W F Wilson; Ralph B D'Agostino
Journal: Circulation Date: 2003-03-25 Impact factor: 29.690

10. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study.

Authors: Stefan Kiechl; Johann Willeit; Manuel Mayr; Brigitte Viehweider; Martin Oberhollenzer; Florian Kronenberg; Christian J Wiedermann; Sabine Oberthaler; Qingbo Xu; Joseph L Witztum; Sotirios Tsimikas
Journal: Arterioscler Thromb Vasc Biol Date: 2007-05-31 Impact factor: 8.311

6 in total

1. Lipoprotein-associated phospholipase A2 is associated with postpartum hypertension in women with history of preeclampsia.

Authors: Yuheng Zhou; Jianmin Niu; Dongmei Duan; Qiong Lei; Jiying Wen; Xiaohong Lin; Lijuan Lv; Longding Chen
Journal: Heart Vessels Date: 2014-04-23 Impact factor: 2.037

2. Long-term darapladib use does not affect coronary plaque composition assessed using multimodality intravascular imaging modalities: a randomized-controlled study.

Authors: Woong Gil Choi; Megha Prasad; Ryan Lennon; Rajiv Gulati; Abhiram Prasad; Lilach O Lerman; Amir Lerman
Journal: Coron Artery Dis Date: 2018-03 Impact factor: 1.439

Role of lipoprotein-associated phospholipase A2 in atherosclerosis.

1. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction.

2. Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein.

3. Platelet-activating factor acetylhydrolase prevents myocardial ischemia-reperfusion injury.

Review 4. Phospholipase A(2) in vascular disease.

5. Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study.

6. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma.

7. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.

8. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.

9. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study.

10. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study.

1. Lipoprotein-associated phospholipase A2 is associated with postpartum hypertension in women with history of preeclampsia.

2. Long-term darapladib use does not affect coronary plaque composition assessed using multimodality intravascular imaging modalities: a randomized-controlled study.

3. Gene expression signatures differ with extent of atherosclerosis in monkey iliac artery.

Review 4. Phospholipase A2 structure/function, mechanism, and signaling.

Review 5. Small-molecule inhibitors as potential therapeutics and as tools to understand the role of phospholipases A₂.

6. Structural Modeling of Wild and Mutant Forms of Human Plasma Platelet Activating Factor-Acetyl Hydrolase Enzyme.

Review 4. Phospholipase A(2) in vascular disease.

Review 4. Phospholipase A2 structure/function, mechanism, and signaling.

Review 5. Small-molecule inhibitors as potential therapeutics and as tools to understand the role of phospholipases A2.

Review 5. Small-molecule inhibitors as potential therapeutics and as tools to understand the role of phospholipases A₂.